DocBot

Irvine, California, United States All United States companies → — Founded 2013

Imaging AI Specialist Revenue Cycle / Billing Specialty-Focused AI

Family Medicine Hospital Medicine Internal Medicine

Series A (last known stage for independent entity)

Website Claim this company

About DocBot

Docbot, Inc. was a pioneering artificial intelligence (AI) technology company dedicated to advancing gastrointestinal (GI) diagnostics and care. Its core offering, the UltivisionAI™ platform, was designed to provide real-time image analysis during endoscopic procedures such as colonoscopies. For gastroenterologists, this meant an AI-assisted tool capable of enhancing the detection of polyps, lesions, and various GI diseases, including Barrett’s esophagus and ulcerative colitis. The platform aimed to augment human capabilities, improving diagnostic accuracy and efficiency, while also streamlining clinical workflows through automated reporting and data-driven analytics.

The company’s mission was to revolutionize GI care by providing powerful AI-assisted image analysis solutions. Docbot collaborated with major pharmaceutical companies, such as Eli Lilly, to explore applications like predicting the severity of ulcerative colitis from endoscopy videos, showcasing its commitment to leveraging AI for deeper clinical insights and improved patient outcomes. The technology was developed to integrate with existing IT systems, aiming to make documentation and billing more efficient, track quality indicators like withdrawal time, and ultimately contribute to earlier detection and prevention of GI cancers.

It is important for physicians to note that Docbot’s intellectual property and assets were strategically acquired by Satisfai Health, Inc. in November 2022. Following this acquisition, key technical employees from Docbot transitioned to Satisfai Health, indicating an integration of Docbot’s innovative AI-driven GI endoscopy solutions into Satisfai Health’s broader product roadmap. Therefore, while the UltivisionAI platform and its underlying technology continue to evolve, they are now part of Satisfai Health’s offerings.

Focus Areas

Gastrointestinal (GI) disease real-time image analysis polyp detection colon cancer prevention Barrett's esophagus ulcerative colitis automated reporting clinical workflow automation AI-assisted diagnostics computer vision endoscopy

Business Intelligence

Technology

UltivisionAI platform (AI-powered software for real-time image analysis, automated reporting, and analytics, machine learning, computer vision)

What Physicians Need to Know

Gastrointestinal (GI) Disease Focus

DocBot specializes in applying artificial intelligence to improve the detection and diagnostic accuracy of gastroenterologists during gastrointestinal endoscopy procedures, aiming to revolutionize GI care.

Real-time Image Analysis

Their UltivisionAIu2122 platform utilizes machine learning and computer vision to highlight suspicious areas on the screen in real-time, guiding gastroenterologists to inspect certain areas more closely during endoscopy.

Polyp Detection & Colon Cancer Prevention

Primarily focused on polyp detection for colon cancer prevention, the system aims to detect lesions that might otherwise be missed, with reported accuracy rates up to 98%.

Barrett's Esophagus & Ulcerative Colitis

DocBot is developing detection algorithms for Barrett's esophagus dysplasia and Ulcerative Colitis, with their UltivisionAI platform capable of automatically predicting ulcerative colitis severity from endoscopy videos.

Automated Reporting & Workflow Automation

The UltivisionAI platform provides automated reporting and data-driven analytic tools to improve patient care and clinical workflows, including auto-documentation features.

AI-Assisted Diagnostics & Computer Vision

At its core, DocBot offers powerful AI-assisted image analysis solutions, leveraging machine learning and computer vision to empower physicians with more reliable and objective detection and diagnosis of GI disease.

Physician Tip

DocBot's UltivisionAI platform offers gastroenterologists real-time, AI-powered assistance during endoscopy, potentially increasing adenoma detection rates and reducing the risk of missed lesions. The system's ability to optically detect precancerous polyps in fractions of seconds, compared to traditional two-week pathology processes, can significantly expedite diagnosis and treatment planning, while also reducing associated costs. Furthermore, its automated reporting features can streamline clinical workflows, freeing up valuable physician time. The continuous learning nature of the AI means its performance is expected to improve over time, offering increasingly accurate and sensitive detection. Physicians can anticipate enhanced diagnostic accuracy and more objective methods for managing various GI conditions, including colon cancer, Barrett's esophagus, and ulcerative colitis.

Specific integration partners or detailed integration methods for DocBot's GI endoscopy AI platform (UltivisionAI) are not explicitly detailed in the provided search results. The company focuses on integrating its AI directly into the endoscopy workflow for real-time analysis.

Products by DocBot

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

DocBot (also referred to as DocsBot AI) is an AI-powered tool primarily designed to create chatbots from existing documentation to automate customer support and streamline document management. It is praised for its user-friendly interface, ease of integration, and ability to provide accurate, context-specific answers. The company also offers a medical coding AI tool called DocBot, which focuses on automating diagnosis coding and improving accuracy for healthcare providers.

Overall: Positive

Strengths

User-friendly interface and easy integration for chatbot creation.
Accurate and context-specific answers from chatbots, reducing hallucinations.
Automates repetitive tasks and streamlines document management, saving time and increasing productivity.
Supports a wide range of content sources for training chatbots, including websites, files, and YouTube transcripts.
Medical coding AI improves risk adjustment accuracy, reduces audit risk, and increases provider satisfaction.
Offers API options for seamless integration with other tools.

Limitations

Some features are limited to premium plans, and pricing can be expensive.
Chatbot accuracy is highly dependent on the quality and structure of the source documentation.
Advanced automation features may require technical expertise to configure.
Limited customization options for chatbot appearance and behavior.
May experience occasional lagging, bugs, or crashes.
Lack of native live chat interface or agent inbox, meaning it's not a full-service support platform.

Based on reviews from: G2, Product Hunt, DocBot Medical Coding AI Website, Reddit, SaaSInspector, Bright SEO Tools, WP Mayor

Last updated: 2026-08-22

Videos

News, demos, and interviews about DocBot.

Loading videos...

Videos load interactively. If none appear, search YouTube for DocBot →

View all on YouTube

Press & Coverage

Business Wire

Docbot Closes Series A Financing Led by Khosla Ventures and Appoints Andrew J. Ritter as CEO

Docbot, an AI technology company focused on gastrointestinal disease, announced the closing of an $4 million Series A funding round, led by Khosla Ventures, bringing their total capital raised to $8.5 million. Concurrently, Andrew J. Ritter was appointed as CEO, with founding CEO Andrew Ninh transitioning to Chief Strategic Officer.

2021-05

Fierce Biotech

Gastrointestinal AI developer Docbot nets new CEO, series A funding for clinical trials

Docbot secured $4 million in Series A funding and a new CEO, Andrew Ritter, to advance clinical trials for its real-time AI programs designed to detect potential cancers during colonoscopies. The funding will also support expanding the company's team and building clinical evidence for its AI program as it prepares for FDA submissions.

2021-05

Mercom Capital Group

Docbot Raises $4 Million for Clinical Decision Support Platform

Docbot closed a $4 million Series A round, led by Khosla Ventures, for its automated software platform, UltivisionAI, which uses AI for real-time computer vision and machine learning detection in gastrointestinal disease. The new capital will be used to advance clinical trials and seek FDA clearance for their investigational device.

2021-05

UCI Beall Applied Innovation

Docbot Exits Y Combinator, Receives $2.045M in Funding

Docbot, a UCI Applied Innovation startup, exited Y Combinator and received $2.045 million in seed funding from investors including Khosla, Lightbridge Ventures, and BOLD Capital Partners. This funding, along with a National Science Foundation grant, will support clinical trials for its AI-enabled platform that identifies colon polyps in real time and aims to expand its use to Barrett's Esophagus.

2019-05

IJRASET

DocBot AI as Your Personal Health Assistant: Bridging the Gap in Consultations Revolutionizing Healthcare Using Natural Language Processing and Artificial Intelligence

This paper explores the DocBot Chat Bot/AI system as a novel solution for acquiring accurate and personalized health information, leveraging AI algorithms and natural language processing to provide tailored advice and preventive steps for various health concerns. The system aims to empower customers with precise and individualized information about their health conditions and appropriate recommendations for additional action.

2024-09

ResearchGate

DocBot: Integrating LLMs for Medical Assistance

This research proposes DocBot, an innovative Large Language Model (LLM) powered medical chatbot, designed to offer comprehensive healthcare support through interactive, conversational engagement. It leverages Mistral.AI and NVIDIA's NeMo Instruct 2407, optimized for biomedical applications through Retrieval Augmented Generation (RAG), to mitigate hallucinations and ensure accurate responses.

2026-08

ResearchGate

Towards Ubiquitous Hospital-Level Personalized Healthcare: Doctor Robot (DocBot)

This paper introduces DocBot, an AI-powered robotic health assistant designed to deliver personalized, proactive care in various settings, aiming to integrate hospital-grade healthcare into daily life. The vision is to combine advanced mechatronics, multi-modal sensing, continuous AI learning, and real-time connectivity to create a mobile, non-invasive health monitoring system.

2025-07

DocBot AI

DocBot - Medical Coding AI

DocBot is a Medical Coding AI assistant that analyzes charts and clinical documentation to automatically identify missed diagnoses, HCC codes, and revenue opportunities, aiming to boost RAF scores and reduce audit risks. It consistently achieves 95u201398% coding accuracy, surpassing traditional human reviewers.

unknown

Frequently Asked Questions

What is Docbot's core product and how does it assist in gastrointestinal (GI) disease diagnosis?

Docbot's primary product is UltivisionAI, an AI-powered software platform designed for real-time image analysis during GI endoscopy procedures, particularly colonoscopies. It uses machine learning and computer vision to highlight suspicious areas, such as polyps and lesions, that might be missed by the human eye, thereby improving diagnostic accuracy.

How does Docbot's UltivisionAI specifically contribute to colon cancer prevention and polyp detection?

UltivisionAI's main focus is on enhancing polyp detection during colonoscopies, which is crucial for colon cancer prevention. The system analyzes endoscopic video feeds in real-time, alerting gastroenterologists to potential adenomas and lesions, which can significantly reduce the rate of missed polyps and associated treatment costs.

Does Docbot's technology address other GI conditions like Barrett's Esophagus or Ulcerative Colitis?

While primarily focused on polyp detection, Docbot is actively developing detection algorithms for other significant GI indications, including Barrett's Esophagus dysplasia and Ulcerative Colitis. The UltivisionAI platform is being trained to be applicable across the entire GI tract.

How does Docbot's platform integrate into existing clinical workflows and offer automated reporting?

UltivisionAI is designed to improve clinical workflows by providing actionable, real-time computer vision detection, automated reporting, and data-driven analytic tools. This integration aims to empower physicians with more reliable data-driven decisions and streamline the documentation process.

What is the current regulatory status of Docbot's UltivisionAI platform, particularly regarding FDA clearance?

Docbot is actively seeking FDA clearance for its UltivisionAI platform and is currently undergoing a national, multicenter clinical trial (the AIDA trial) to prospectively validate its technology for adenoma detection. As of earlier reports, the platform was indicated for investigational use only, with the trial results intended to support a De Novo application submission.

Can you provide information on Docbot's company stability, funding, and any notable partnerships?

Docbot, founded in 2014, raised a total of $8.5 million in equity funding, including a $4 million Series A round in May 2021, with backing from investors like Khosla Ventures and Y Combinator. The company was acquired by Satisfai Health in 2022, indicating a new phase of company stability and integration within a larger entity.

Investors

Who's funded DocBot.

Inovabra Ventures is the corporate venture arm of Bradesco, one of Brazil’s largest financial groups, investing into startups that can modernize the…

Digital Health Health IT / Healthcare Software

Related Companies

Suggest an Edit → | Report an issue